Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 387 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depression in Adults Clear all
Completed Not applicable Interventional

Feasibility of an Exercise Intervention

NCT01984060
View directory record Official record
Conditions
HIV
Interventions
HOME-EX
Other
Lead sponsor
University of Rochester
Other
Eligibility
45 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

NCT04669665
View directory record Official record
Conditions
Depressive Disorder, Major, Suicidal
Interventions
SLS-002, Placebo, Standard of care, Intranasal device
Drug · Other · Device
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Orange, California • Panorama City, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

NCT01360866
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

ALTO-300 in Depression (ALTO-300-004)

NCT05157945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-300 PO Tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 74 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Jackson, Mississippi • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 9, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

NCT07276997
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Icalcaprant, Placebo for Icalcaprant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Disparities in Late Life Depression and Metabolic Syndrome

NCT01428791
View directory record Official record
Conditions
Depressive Symptoms, Metabolic Syndrome X, Overweight, Obesity, Hypertension, Hyperglycemia, Dyslipidemias
Interventions
Generations older adult membership program, BRIGHTEN Heart Virtual Team intervention
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
60 Years to 110 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 9, 2026, 8:30 AM EDT
Terminated Not applicable Interventional Results available

Combination Lexapro and Massage for Treatment of Depression in Older Adults

NCT00643162
View directory record Official record
Conditions
Depression
Interventions
Lexapro, Light touch, Massage
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 9, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT07494305
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
LB-102, Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

NCT00863798
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg, placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Encino, California • Newport Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline

NCT06466655
View directory record Official record
Conditions
Middle-aged Adults, Major Depressive Disorder
Interventions
MitoTempol, Lactated Ringer's (control)
Drug
Lead sponsor
University of Delaware
Other
Eligibility
40 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 9, 2026, 8:30 AM EDT
Recruiting Not applicable Interventional

Enhancing Slow Wave Sleep in Depression

NCT07143838
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Transcranial Electrical Stimulation (TES)
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

ALTO-100 in MDD and/or PTSD

NCT05117632
View directory record Official record
Conditions
Major Depressive Disorder, Post Traumatic Stress Disorder
Interventions
ALTO-100 PO tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 69 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Tempe, Arizona • Little Rock, Arkansas • Costa Mesa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 9, 2026, 8:30 AM EDT
Terminated Phase 3 Interventional

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

NCT06514742
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 9, 2026, 8:30 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Reducing the Risk of Developing Major Depression in Adolescents/Young Adults With Minor Depression/Depression Symptoms

NCT00145951
View directory record Official record
Conditions
Depression
Interventions
motivational interviewing, brief advice in primary care
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

NCT05203341
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, NBI-1065845
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Huntsville, Alabama • Riverside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

NCT02371980
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 9, 2026, 8:30 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust

NCT01874834
View directory record Official record
Conditions
Respiratory Depression, Blood Pressure
Interventions
ozone
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Not applicable Interventional

Medication Adherence in Older Adults With Serious Mental Illness

NCT00224380
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression
Interventions
Using Medications Effectively
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Nashua, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 22, 2009 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults

NCT01973283
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
Interventions
Antidepressant Medication
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Stress and the Sympathetic Nervous System in Adults With Depression

NCT04838262
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Acute Stressors
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 30 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

NCT06057012
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
BRII-296, Depo Medrol
Drug
Lead sponsor
Brii Biosciences Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
11
States / cities
Sherman Oaks, California • Torrance, California • Boynton Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 9, 2026, 8:30 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05550532
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
51
States / cities
Birmingham, Alabama • Lafayette, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 9, 2026, 8:30 AM EDT